Kyntra Bio posts Q3 profit and cuts royalty payments while seeking Phase 3 funding

Kyntra Bio reported third‑quarter 2026 net income of $0.2 million, or $0.04 per share, reversing a $13.1 million loss a year earlier. Revenue was $1.8 million. The company restructured its royalty financing agreement, lowering the maximum royalty obligation to $15 million and cutting the cap from $125 million to $65 million, and said it expects more than $20 million of operating‑expense savings. The planned Phase 3 roxadustat trial for LR‑MDS patients will proceed only if a strategic partnership or external capital raise is secured.

The royalty reduction and projected expense savings improve cash runway, extending it into 2028 per the filing. However, the Phase 3 trial’s funding uncertainty creates execution risk for the company’s lead product.

  • 1Q3 2026 net income was $0.2 million, or $0.04 per share.
  • 2Q3 2026 revenue was $1.8 million.
  • 3Cash and receivables at September 30, 2026 totaled $44.1 million.
  • 4Maximum royalty payments were reduced from $125 million to $65 million, leaving a remaining cap of $15 million.
  • 5The company expects operating‑expense savings of over $20 million in 2027 and 2028.
  • 6The Phase 3 roxadustat trial is planned for 1Q 2027 and depends on securing a partnership or external capital raise.

Sources